title: Clinical utility of ketoconazole in cases of adrenocortical carcinoma.
abstract: Ketoconazole, an imidazole derivative is known to decrease adrenal steroid biosynthesis by inhibiting cytochrome P450 dependent adrenal enzymes. Three patients of adrenal carcinoma treated with ketoconazole, 600-1200 mg daily showed significant fall in plasma and urinary cortisol levels, but no reduction in tumor size, one patient developed liver dysfunction which reverted back to normal on discontinuing the drug.
authors.affiliation: Department Of Endocrinology & Metabolism, All India Institute of Medical Sciences, New Delhi.
authors.forename: C V
authors.initials: CV
authors.lastname: Harinarayan
authors.forename: S
authors.initials: S
authors.lastname: Gupta
authors.forename: A C
authors.initials: AC
authors.lastname: Ammini
authors.forename: M G
authors.initials: MG
authors.lastname: Karmarkar
authors.forename: R
authors.initials: R
authors.lastname: Gupta
authors.forename: L K
authors.initials: LK
authors.lastname: Sharma
authors.forename: M M
authors.initials: MM
authors.lastname: Ahuja
mesh_terms: D000293:Adolescent; D000306:Adrenal Cortex Neoplasms / Q000188:drug therapy*; D000328:Adult; D002648:Child; D005260:Female; D006801:Humans; D007654:Ketoconazole / Q000627:therapeutic use*; D008297:Male
chemical_list: D007654:Ketoconazole